Penn Medicine Researchers Find Much Stronger Association Between Alcohol Use and Advanced Liver Fibrosis in Patients Compared to Uninfected

facebook twitter google print email
Media Contact:Steve Graff | stephen.graff@uphs.upenn.edu | 215-349-5653May 2, 2014

Consumption of alcohol has long been associated with an increased risk of advanced liver fibrosis, but a new study published in the May issue of Clinical Infectious Diseases from researchers at Penn Medicine and other institutions shows that association is drastically heightened in people co-infected with both HIV and chronic hepatitis C virus (HCV) infection.  Even light (“nonhazardous”) drinking—which typically poses a relatively low risk for uninfected persons—was linked to an increased risk of liver fibrosis in the co-infected group.

Reasons for this are not fully understood, but preclinical studies have shown that the two viruses can induce liver cell death and that adding alcohol may accelerate that process and more quickly lead to severe liver fibrosis. Toxicity to the liver from antiretroviral drugs may also be exacerbated by alcohol.

 “We’ve shown a much greater risk for coinfected compared to uninfected persons at all levels of alcohol consumption—from nonhazardous drinking up to hazardous/binge drinking and abuse/dependence,” said senior author Vincent Lo Re III, MD, MSCE, assistant professor of Medicine and Epidemiology in the division of Infectious Diseases and department of Biostatistics and Epidemiology at Penn and an infectious disease physician at the Veteran Affairs Medical Center in Philadelphia. “This highlights how important it is for clinicians to be counseling co-infected patients on reducing alcohol consumption. More communication and education about the risks of alcohol may prompt patients to reduce drinking or quit altogether, which will help reduce the incidence of complications.”

Few studies have investigated the association between alcohol and liver disease in HIV/HCV-co-infected patients, and none have compared risks to uninfected persons.

For the study, researchers, which included first author Joseph K. Lim, MD, of the Yale University School of Medicine and the Veterans Affairs Connecticut Healthcare System, conducted a cross-sectional study among 7,270 participants from the Veterans Aging Cohort Study: 701 HIV/HCV co-infected; 1,410 HIV-mono-infected; 296 HCV-mono-infected; and 1,158 uninfected.  Alcohol use was determined by the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaire and diagnoses of alcohol abuse/dependence and classified as nonhazardous drinking, hazardous/binge drinking, and alcohol-related diagnosis.

The team found that regardless of HIV or HCV status, the prevalence of advanced hepatic fibrosis increased as alcohol use category increased. However, the strongest associations were observed in co-infected patients across all alcohol categories compared with uninfected non-hazardous drinkers. 

Click here to view the full release.

Multimedia